Gossamer Bio (GOSS) Current Assets (2018 - 2026)
Gossamer Bio (GOSS) posted quarterly Current Assets of $124.5 million for Q1 2026, down 54.79% year-over-year from $275.5 million in Q1 2025, and down 25.71% quarter-over-quarter from $167.6 million in Q4 2025.
Gossamer Bio (GOSS) Current Assets (2018 - 2026) Analysis & Trends
Gossamer Bio's Current Assets history runs 9 years deep, the most recent figure standing at $124.5 million for Q1 2026.
- In Q1 2026, Current Assets fell 54.79% year-over-year to $124.5 million; the TTM figure through Mar 2026 stood at $124.5 million (down 54.79% YoY), while the FY2025 annual figure was $167.6 million, down 45.9% from the prior year.
- Current Assets for Q1 2026 stood at $124.5 million, down from $167.6 million in the prior quarter.
- The five-year high for Current Assets was $370.9 million in Q2 2024, with the low at $124.5 million in Q1 2026.
- The 5-year median for Current Assets is $261.9 million (2022), against an average of $259.2 million.
- The sharpest annual moves came in 2024 and 2026: Current Assets surged 113.93% in 2024, then tumbled 54.79% in 2026.
- Gossamer Bio's Current Assets stood at $261.9 million in 2022, then rose by 17.05% to $306.5 million in 2023, then gained by 1.1% to $309.9 million in 2024, then tumbled by 45.9% to $167.6 million in 2025, then dropped by 25.71% to $124.5 million in 2026.
- Business Quant data shows GOSS's Current Assets at $124.5 million in Q1 2026, $167.6 million in Q4 2025, and $204.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.62 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.63 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 1.76 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 18.80 Bn |
| 10 | Gossamer Bio | 50.34 Mn | -6.69 Mn | - | 72.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 72.73 Mn |
| Mar 31, 2026 | 124.54 Mn |
| Dec 31, 2025 | 167.64 Mn |
| Sep 30, 2025 | 203.99 Mn |
| Jun 30, 2025 | 235.90 Mn |
| Mar 31, 2025 | 275.48 Mn |
| Dec 31, 2024 | 309.89 Mn |
| Sep 30, 2024 | 344.27 Mn |
| Jun 30, 2024 | 370.90 Mn |
| Mar 31, 2024 | 255.27 Mn |
| Dec 31, 2023 | 306.52 Mn |
| Sep 30, 2023 | 341.49 Mn |
| Jun 30, 2023 | 173.38 Mn |
| Mar 31, 2023 | 210.41 Mn |
| Dec 31, 2022 | 261.88 Mn |
| Sep 30, 2022 | 312.03 Mn |
| Jun 30, 2022 | 232.68 Mn |
| Mar 31, 2022 | 280.77 Mn |
| Dec 31, 2021 | 331.78 Mn |
| Sep 30, 2021 | 373.99 Mn |